Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: To establish the safety profile and antitumor activity of the anti–programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) that expressed programmed death-ligand 1 (PD-L1). Patients and Methods: KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1–positive advanced solid tumors. Key eligibility criteria for the NPC cohort included unresectable or metastatic disease, failure on prior standard therapy, and PD-L1 expression in 1% or more of tumor cells or tumor-infiltrating lymphocytes. Patients received pembrolizumab 10 mg/kg every 2 weeks up to 2 years or until disease progression or unacceptable toxicity. Primary end point was objective response rate (ORR) per investigator review. Tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) every 8 weeks for the first 6 months and every 12 weeks thereafter. Results: Twenty-seven patients received pembrolizumab. Median age was 52.0 years (range, 18 to 68 years); 92.6% received prior therapies for RM-NPC; 70.4% had received three or more therapies. Partial response and stable disease were observed in seven and 14 patients, respectively, for an ORR of 25.9% (95% CI, 11.1 to 46.3) over a median follow-up of 20 months. ORR by central review was similar (26.3%). Drug-related adverse events that occurred in 15% or more of patients included rash (25.9%), pruritus (25.9%), pain (22.2%), hypothyroidism (18.5%), and fatigue (18.5%). Grade ≥ 3 drug-related adverse events occurred in eight patients (29.6%), and there was one drug-related death (sepsis). As of the data cutoff (June 20, 2016), two patients remained on pembrolizumab treatment. Conclusion: Pembrolizumab demonstrated antitumor activity and a manageable safety profile in patients with RM-NPC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745
Self-citationLanger, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
The Enigmatic Epidemiology of Nasopharyngeal Carcinoma
Chang, E. T., & Adami, H.-O. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0353 · Cited by 1,297
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,121
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
Self-citation
Cited by
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Self-citationWang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Cohen, E. E. W., Bell, R. B., Bifulco, C. B., Burtness, B., Gillison, M. L., Harrington, K. J., Le, Q.-T., Lee, N. Y., Leidner, R., Lewis, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0662-5 · Cited by 722
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
Colevas, A. D., Yom, S. S., Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., Brizel, D. M., Burtness, B., Busse, P. M., Caudell, J. J., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0026 · Cited by 614
Nasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Fang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 489
Chen, Y.-P., Yin, J.-H., Li, W.-F., Li, H.-J., Chen, D.-P., Zhang, C.-J., Lv, J.-W., Wang, Y.-Q., Li, X.-M., Li, J.-Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0374-x · Cited by 463
Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., Zhou, T., Shen, L., Wu, H., Lang, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00302-8 · Cited by 462
The Global Landscape of EBV-Associated Tumors
Shannon-Lowe, C., & Rickinson, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00713 · Cited by 459
Ma, B. B. Y., Lim, W.-T., Goh, B.-C., Hui, E. P., Lo, K.-W., Pettinger, A., Foster, N. R., Riess, J. W., Agulnik, M., Chang, A. Y. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0388 · Cited by 451
Bossi, P., Chan, A. T., Licitra, L., Trama, A., Orlandi, E., Hui, E. P., Halámková, J., Mattheis, S., Baujat, B., Hardillo, J., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.12.007 · Cited by 447
Tang, L., Chen, Y., Chen, C., Chen, M., Chen, N., Chen, X., Du, X., Fang, W., Feng, M., Gao, J., et al. (2021) · Cancer Communications · doi:10.1002/cac2.12218 · Cited by 413
Mai, H.-Q., Chen, Q.-Y., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y.-R., Jin, F., Xu, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01444-0 · Cited by 396
Management of locally recurrent nasopharyngeal carcinoma
Lee, A. W. M., Ng, W. T., Chan, J. Y. W., Corry, J., Mäkitie, A., Mendenhall, W. M., Rinaldo, A., Rodrigo, J. P., Saba, N. F., Strojan, P., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101890 · Cited by 371
Wang, F.-H., Wei, X.-L., Feng, J., Li, Q., Xu, N., Hu, X.-C., Liao, W., Jiang, Y., Lin, X.-Y., Zhang, Q.-Y., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02712 · Cited by 348
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342
Translational genomics and recent advances in oral squamous cell carcinoma
Chai, A. W. Y., Lim, K. P., & Cheong, S. C. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.011 · Cited by 298
Liu, Y., He, S., Wang, X.-L., Peng, W., Chen, Q.-Y., Chi, D.-M., Chen, J.-R., Han, B.-W., Lin, G.-W., Li, Y.-Q., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21043-4 · Cited by 291
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03600-2 · Cited by 122
“The established standard treatments, including docetaxel or PD-1 inhibitors for immune checkpoint inhibitor (ICI)-naive/treated recurrent or metastatic NPC, exhibit ORRs ranging from 23.5% to 36.7% 27,28 .”
InfluentialBiomarkers for Response to Immune Checkpoint Blockade
Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51
Self-citation
Metadata
- Authors
- Hsu, C., Lee, S.-H., Ejadi, S., Even, C., Cohen, R. B., Le Tourneau, C., Mehnert, J. M., Algazi, A., van Brummelen, E. M. J., Saraf, S., Thanigaimani, P., Cheng, J. D., & Hansen, A. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-12-20
- Volume
- 35
- Issue
- 36
- Pages
- 4050-4056
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2747272999
- Cited by
- 464
- References
- 24
- FWCI
- 15.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.